Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
Table 6
Comparison of BCVA change from baseline between the treatment-naïve subgroup and previously treated subgroup.
Timepoint
Treatment-naïve subgroup
Previously treated subgroup
value
Year
Month
n
BCVA change from baseline, mean (LogMAR) ± SD
n
BCVA change from baseline, mean (LogMAR) ± SD
3
121
−0.12 ± 0.45
59
0.00 ± 0.20
0.0466
6
121
−0.21 ± 0.46
59
0.04 ± 0.28
0.0001
1
12
121
−0.15 ± 0.53
59
0.08 ± 0.41
0.0041
18
116
−0.20 ± 0.52
57
0.02 ± 0.37
0.0037
2
24
116
−0.18 ± 0.54
56
0.13 ± 0.46
0.0002
30
116
−0.20 ± 0.51
55
0.10 ± 0.47
0.0002
3
36
101
−0.19 ± 0.53
54
0.17 ± 0.50
0.0001
42
87
−0.16 ± 0.54
48
0.06 ± 0.53
0.0217
4
48
49
−0.17 ± 0.57
43
0.11 ± 0.52
0.0155
54
44
−0.10 ± 0.63
38
0.15 ± 0.52
0.0595
5
60
28
−0.09 ± 0.71
27
0.14 ± 0.33
0.0444
66
26
−0.10 ± 0.76
24
0.17 ± 0.55
0.1556
6
72
15
−0.07 ± 0.41
17
0.23 ± 0.50
0.0414
78
12
−0.18 ± 0.38
14
0.19 ± 0.53
0.0512
7
84
4
0.06 ± 0.63
5
0.10 ± 0.42
—
Sample size too small to conduct statistical analysis.
